Great Novel Therapeutics Biotech & Medicals (TPEX:7427)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
40.10
-0.80 (-1.96%)
Apr 29, 2026, 1:58 PM CST

TPEX:7427 Ratios and Metrics

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Market Capitalization
1,7221,3741,4842,5621,823936
Upgrade
Market Cap Growth
-6.04%-7.38%-42.09%40.55%94.83%-
Upgrade
Enterprise Value
1,2828838842,0631,731777
Upgrade
Last Close Price
40.1030.3932.2960.9752.0933.38
Upgrade
PS Ratio
1429.351140.63880.65528.303376.081485.29
Upgrade
PB Ratio
3.422.732.344.796.594.49
Upgrade
P/TBV Ratio
3.622.892.455.076.987.81
Upgrade
EV/Sales Ratio
-732.61524.33425.313205.061233.73
Upgrade
Debt / Equity Ratio
0.020.020.020.03--
Upgrade
Net Debt / Equity Ratio
-0.87-0.87-0.90-0.87-0.89-0.60
Upgrade
Net Debt / EBITDA Ratio
4.794.795.277.323.693.57
Upgrade
Net Debt / FCF Ratio
5.015.017.257.993.213.68
Upgrade
Asset Turnover
0.000.000.000.010.000.00
Upgrade
Inventory Turnover
0.460.460.15---
Upgrade
Quick Ratio
23.1923.1926.7729.9520.565.79
Upgrade
Current Ratio
24.1224.1227.4330.4720.875.80
Upgrade
Return on Equity (ROE)
-17.16%-17.16%-17.97%-15.04%-27.68%-21.80%
Upgrade
Return on Assets (ROA)
-10.46%-10.46%-11.51%-9.68%-16.58%-12.83%
Upgrade
Return on Capital Employed (ROCE)
-19.60%-19.60%-17.60%-12.10%-24.90%-17.50%
Upgrade
Earnings Yield
-5.66%-7.09%-7.07%-2.38%-3.68%-3.83%
Upgrade
FCF Yield
-5.10%-6.39%-5.32%-2.26%-4.23%-3.63%
Upgrade
Buyback Yield / Dilution
-4.82%-4.63%-13.60%-50.23%-14.54%-33.09%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.